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Pulmonary Arterial Hypertension
A Novel Therapeutic Target?*Lewis J. Rubin, MDSEE PAGE 668C onsiderable success has been achieved in thetreatment of pulmonary arterial hyperten-sion (PAH) over the past 15 years, with 9
drugs approved by the U.S. Food and Drug Administra-
tion and other regulatory agencies worldwide for use
by several different modes of delivery and lung trans-
plantation becoming an option for patients refractory
tomedical therapy (1). Quality of life and survival rates
are improved, and recent studies have shown that
newer therapies also reduce the risk of hospitaliza-
tions for worsening of PAH (2), an expensive and
ominous event for patients with this condition (3).
Nevertheless, overall survival with PAH is poor, with
estimates of 5-year survival of <60% in recent regis-
tries (4,5). Additionally, all currently approved PAH
therapies target 1 of 3 dysfunctional pathways: endo-
thelin, nitric oxide, and prostacyclin. Accordingly,
novel treatments that target other likely pathogenic
pathways in PAH are needed if further advances in
therapy for PAH are to be achieved.
Studies that use tissue from PAH patients have
demonstrated that pulmonary vascular endothelial
and smooth muscle cells manifest a hyper-
proliferative phenotype that is associated with a
pattern of enhanced expression of a variety of growth
factors and altered intracellular metabolism (6,7) and
have identiﬁed a number of novel targets for thera-
peutic intervention. Several of these novel targets
have been investigated in animal models of PAH with*Editorials published in the Journal of the American College of Cardiology
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of this paper to disclose.encouraging results, although clinical trials have been
disappointing because of off-target serious adverse
effects and less dramatic clinical effects than had
been anticipated. The latter observation underscores
the complexity of PAH pathogenesis that is not
duplicated by animal models. Additionally, the crit-
ical role of progressive right ventricular dysfunction
in the natural history of PAH has not been empha-
sized until recently (8) and has therefore not yet been
explored as an additional important therapeutic
target in this condition.In this issue of the Journal, Perros et al. (9) provide
evidence that the b-adrenergic receptor may be a
novel target for therapy in PAH. In experiments that
used pulmonary vascular cells harvested from PAH
patients undergoing lung transplantation, isolated
vascular rings obtained from normal rats, and in the
monocrotaline-induced model of PAH, they demon-
strate that nebivolol, a drug with b2,3-adrenegic
agonist and b1-antagonist properties, alters the hyper-
proliferative phenotype, reduces the overexpression
of growth and pro-inﬂammatory mediators, produces
a nitric oxide–mediated pulmonary vasodilation, and
attenuates the hemodynamic severity of PAH and
right ventricular hypertrophy—a proﬁle that would
address a number of processes that are likely to be
relevant to the cascade of PAH pathogenesis and
outcome. The effects of nebivolol appear to be due to
its multiple effects on the b-adrenergic receptor,
because b-blockade alone with metoprolol did not
produce similar results. Speciﬁcally, b3-adrenergic
receptor blockade by nebivolol could enhance endo-
thelial nitric oxide production that would reverse
endothelial nitric oxide uncoupling and the genera-
tion of reactive oxygen species that may contribute to
FIGURE 1 Effects of the Beta-3-Adrenergic Receptor on the Pulmonary Vascular
Endothelial Cell
Activation of the receptor, i.e., by nebivolol, increases nitric oxide production, leading to pul-
monary vasodilation andattenuatedvascular remodeling.b3-AR¼beta-3-adrenergic receptor;
Ca ¼ calcium; CAMP ¼ cyclic adenosine monophosphate; CGMP¼ cyclic guanosine mono-
phosphate; eNOS¼ endothelial nitric oxide synthase; GTP ¼ guanosine triphosphate;
N¼nebivolol;NO¼nitricoxide;ROS¼ reactiveoxygenspecies;SGC¼ solubleguanylatecyclase.
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682the endothelial dysfunction and vascular prolifera-
tion that is characteristic of PAH (Figure 1). The
studies by Perros and colleagues suggest that the
b-adrenergic receptor may represent a novel thera-
peutic target in PAH and that clinical investigation
with nebivolol or drugs with a similar pharmacologic
proﬁle is warranted.
The authors wisely caution against prematurely
incorporating drugs acting on the b-adrenergic re-
ceptor into the treatment strategy for PAH patients
until more data are available. Because PAH remains a
serious and life-threatening disease, many patients
and their physicians look to promising therapies for
off-label use, emphasizing the upside and minimizing
the downside. Such was the case for imatinib, a
tyrosine-kinase inhibitor approved for the treatment
of leukemia and other malignancies that showed
promise as a novel PAH treatment on the basis of
preclinical studies demonstrating an inhibitory effect
on platelet-derived growth factor and dramatic ef-
fects in the monocrotaline model (10). The develop-
ment of imatinib for PAH was discontinued, however,
when formal clinical trials demonstrated that the
overall risk-beneﬁt proﬁle in PAHwas unfavorable and
that serious adverse effects were encountered (11).Although nebivolol appeared to be safe in the
monocrotaline model of PAH, the effects of tar-
geting the b-adrenergic system in PAH patients
are unknown andwarrant concern. An activated renin-
angiotensin-aldosterone system in PAH may con-
tribute to pathogenesis, but it may be compensatory
as well, reﬂecting a means by which cardiac output
and systemic perfusion is maintained in the face of a
failing right ventricle through tachycardia and sys-
temic vasoconstriction (12,13). Interfering with these
adaptations could be consequential unless other
pathogenic processes are targeted concurrently.
It is also unclear at this point whether the vaso-
dilatory effects of nebivolol are a boon or bust. This
effect, apparently mediated by stimulating nitric ox-
ide, may not be relevant for most patients with PAH, in
which pulmonary vascular endothelial nitric oxide
production is absent (14) whereas systemic vascular
activity is preserved. Whereas in the long run the
overall effects of nebivolol may result in restoration of
pulmonary vascular endothelial function and nitric
oxide–mediated vasorelaxation, the short-term sys-
temic vasodilatory effects could pose a challenge.
Finally, in the studies by Perros et al. (9), nebivolol
attenuated the development of pulmonary hyperten-
sion in themonocrotalinemodel when administered to
animals during the course of disease development af-
ter monocrotaline administration, but this is hardly
analogous to the clinical setting, in which patients
present with signs and symptoms only once estab-
lished, advanced pulmonary vasculopathy has resul-
ted in right ventricular compromise.
A key issue will be the selection of patients for
early trials with nebivolol or similar third-generation
adrenergic receptor agents: Patients with advanced
disease, manifested by more severe right ventricular
dysfunction and greater stimulation of the b-adren-
ergic system (15), have fewer treatment options at
present and may be more likely to exhibit clear
beneﬁt in short, proof-of-concept trials, but they may
also be at greater risk for off-target drug effects.
Alternatively, those with less severe disease and
preserved right heart function may manifest more
substantial beneﬁts, but these probably will require
long-term observation. Either way, only carefully
performed clinical trials will clarify whether or not
drugs that target the b-adrenergic system can be
added to our treatment armamentarium for PAH.
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